Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the acquisition of Daxor's BVA-100 blood volume analyzer as part of standard clinical practice in a leading academic health center in the Pacific Northwest following a successful evaluation trial. “The BVA-100 provides a simple, inexpensive, objective measurement of volume status and composition,” said Michael Feldschuh, CEO of Daxor Corporation. "We are pleased to provide physicians at this leading hospital with accurate, actionable volume information to better inform treatment strategies leading to optimal patient outcomes and improved quality of life. Important considerations for the adoption of our system included reimbursement for Medicare and private insurance as well as use at other leading hospitals across the country.” About Daxor Corporation Daxor Co
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum [Yahoo! Finance]Yahoo! Finance
- Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales MomentumGlobeNewswire
- DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24GlobeNewswire
- Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewswire
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device [Yahoo! Finance]Yahoo! Finance
DXR
Sec Filings
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- DXR's page on the SEC website